Dysautonomia and Systemic Interactions in Traumatic Brain Injury (DYSI-TBI)
Study Overview
Status
Detailed Description
Following traumatic brain injury (TBI) complex interactions between the nervous system and other organs are frequently encountered. Systemic reactions may be induced by dys-regulation of the hypothalamic-pituitary adrenal (HPA) axis and the autonomic nervous system. Neuro-endocrine disturbances are common and up to 50 % of brain injured Neuro-intensive care (NICU) patients may exhibit a period of relative adreno-cortico insufficiency in the early phase of TBI, which in part may be centrally mediated. Catecholamine surge is thought responsible for cardio pulmonary reactions such as myocardial stunning, and may be an instrumental part of neurogenic pulmonary edema. An imbalance between the parasympathetic and sympathetic nervous system has been identified, and may even effect outcome, but is poorly understood. This is seen both in early and chronic stages of brain injury. Heart rate variability has been implicated as an indicator of dys-autonomic parasympathetic dysfunction, and has in small studies been related to TBI outcome. Recently a clinical definition of Paroxysmal Sympathetic Hyper-activation (PSH) has been suggested and identities as related to patient outcome.
Thus, in TBI the picture of a triad of dysautonomic and hypothalamic-pituitary dysregulation and injury driven inflammation, with a potential of bi-directional cross-talk between central and peripheral immuno- modulators, is emerging. This study will aim to explore and integrate indicators of these three components as to define phenotypes. It will investigate the utility of medically approved (CE) Skin Conductance Algesimeter (Med-Storm ®) in relation to other parameters of physiological stress including, heart rate variability (HRV), intra-cranial pressure reactivity index (PrX), and products of the HPA axis such as, ACTH, adrenaline and nor-adrenaline including break down products, markers of brain trauma driven neuro and systemic inflammation.
The investigators hypothesize that a limited number of composite patterns will emerge and may describe patient phenotypes with differing trajectories.
CRF:
Electronic case report form (eCRF) with pseudo anonymized data via a globally unique personal identifier (GUPI) to secure eCRF platform.
Patient Key kept locally and GDPR compliant.
Variables:
Baseline variables including IMPACT calculator variables for co-variate adjustment and trauma time, including predictors from the from Karolinska Traumatic Brain injury Database.
Additional parameters of injury severity assessment and outcome predictors: Intracranial injury severity scoring on computed tomography (CT) scan by abbreviated injury severity score, Marshall CT classification, Rotterdam CT score, Helsinki CT score and Stockholm CT score.
Severity scoring on magnetic resonance imaging (MRI) (if available) focusing on the presence of diffuse axonal injury (DAI), burden and region of DAI.
Concomitant drugs of interest, such as analgesics, sedation, alpha II agonists, betablockers, vasopressor support.
Daily injury severity scores. Daily symptom assessment of paroxysmal sympathetic hyperactivity (PSH) in relation to guideline definition.
Daily Therapy Intensity level (TIL) and individual components. Daily Pain assessment scores. Available relevant clinical lab data in hospital system such as S100B, ProBNP, Troponins TSH,T3,T4.
High resolution physiological data, physiological monitoring during ICU stay. Physiological monitoring via ICM+ including intracranial pressure (ICP), Brain tissue oxygenation (PbtO2), ECG waveform and heart rate variability (HRV), Central Temperature (Temp) , Saturation (SaO2). Pulse reactivity Index (PrX).
Med-Storm Skin Conductance Algesimeter measure of sympathetic activity. ICM + ® annotation tool: Time-stamped changes in sedation and potentially painful and stressful clinical interventions.
Bio-sampling:
Biomaterial bio-banked for analyses Collection of plasma (from 4 ml whole blood sample) Daily, day 1-7, sampled from arterial line when available clinically.
Cerebral Microdialysis: hourly when clinically available, pooled. Cerebral spinal fluid(CSF): Daily (2 ml), when clinically available from EVD catheter, day 1-7.
Urine: Daily mixed aliquot (20 ml) of a 6 hour measured collection, day 1-7. Samples centrifuged 20G-15min: Aliquots of 200 μl and frozen with sample to freezer time recorded.
Outcome Follow-up:
Extended Glasgow Outcome Scale (GOSE) questionnaire and/or interview at 3, 6 and 12 months. Extraction from Karolinska Traumatic Brain injury Database.
Death Date.
Planned analyses:
Wet-lab Proteomics: protein profiling of brain enriched and inflammatory proteins from serum, CSF and cerebral microdialysis.
Microparticles/ exosomes, microRNA of central origin in CSF, microdialysate and plasma.
HPA axis parameters and breakdown products including cortisol, catecholamines, metanephrines.
Specific parameters of inflammatory crosstalk periphery/brain including choline acetyl transferase, HMGB1 as well as peripheral and central modulators of levels of T and B cell subgroup and glial activation.
Analytics:
Signal decomposition of physiological variables: ECG derived metrics including decreased baroreflex sensitivity (BRS), low frequency (LF), high frequency (HF) and total power (TP). Entropy. HRV. Signal analysis including FFT and wavelet.
ICP derived metrics including PrX. Dimensionality reduction techniques such as principle component analysis (PCA) and non-supervised clustering techniques.
Time series analyses: Cross-correlations and Trajectory analyses, Deep learning
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Perioperative Medicine and Intensive Care, Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 years or over.
- Patients suffering from TBI, in need of neurocritical care and intracranial pressure measurement
Exclusion Criteria:
- Trauma more than 24 hours prior to inclusion. Goal for inclusion is less than 12 hours.
- TBI unlikely to survive five days (as judged by clinical team, such as bilateral fixed and dilated pupils).
- Follow up not possible
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Karolinska Cohort
Observational cohort corresponding to patients treated at the Neurointensive Care Unit, Karolinska University Hospital, Stockholm, Sweden.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Conductance Algesimeter
Time Frame: up to one week
|
the Skin Conductance Algometer (MedStorm (R)) as conductance in microvolts and algesimeter index as peaks/second.
|
up to one week
|
|
Stress biomarkers
Time Frame: up to one week in ICU
|
Cortsol and adrengeric breakdown metabolites
|
up to one week in ICU
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory hypothesis-generating analysis of interactions/crosstalk between dysautonomia, the hypothalamic-pituitary-adrenal axis and neuroinflammation.
Time Frame: Collected during ICU stay up to one week.
|
As to elucidate if indices of systemic sympathetic activation in severe TBI can be used to monitor expression of paroxysmal sympathetic hyperactivity, multiple cross-correlations of time series data will explored to better understand temporal associations.
Thus a specific outcome is not sought but strengths of temporal associations.
This will also include dimensionality reduction reduce and identify a finite number of phenotypes with clustering techniques.
|
Collected during ICU stay up to one week.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Extended Glasgow Outcome Scale (EGOS)
Time Frame: 4-6 months
|
EGOS will be recorded at 4-6 months for demographic purposes, however sample size does not permit analysis related to this outcome
|
4-6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David W Nelson, M.D., Ph.D., Karolinska University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Neuroinflammatory Diseases
- Encephalitis
- Inflammation
- Brain Injuries
- Wounds and Injuries
- Brain Injuries, Traumatic
- Primary Dysautonomias
- Autonomic Nervous System Diseases
Other Study ID Numbers
- 2019-5610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.